Pancreatic carcinogenesis: apoptosis and angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Apoptosis and angiogenesis are crucial biological processes dysregulated in carcinogenesis, particularly in pancreatic cancer.
• Pancreatic cancer's poor prognosis necessitates novel therapeutic strategies, as current treatments remain limited.
• Tumor growth is critically dependent on angiogenesis, making it a key target for cancer therapy.

Purpose of the Study:

• To identify and characterize novel angiogenesis inhibitors from human pancreatic carcinoma cells.
• To evaluate the therapeutic potential of these inhibitors in preclinical models of pancreatic cancer.
• To explore the role of apoptosis and angiogenesis interplay in pancreatic carcinogenesis.

Main Methods:

• Isolation and identification of angiogenesis inhibitors from conditioned medium of human pancreatic carcinoma cell line (BxPC-3).
• In vitro assessment of endothelial cell proliferation inhibition.
• In vivo evaluation of tumor regression and dormancy induction in severe combined immunodeficiency disease (SCID) mice.

Main Results:

• Two novel angiogenesis inhibitors were identified: antiangiogenic antithrombin III (aaAT-III) and vitamin D binding protein-macrophage activating factor (DBP-maf).
• These inhibitors demonstrated potent inhibition of endothelial cell proliferation.
• aaAT-III and DBP-maf induced significant tumor regression and tumor dormancy in SCID mice.

Conclusions:

• aaAT-III and DBP-maf are potent inhibitors of angiogenesis and possess anti-tumor activity.
• Anti-angiogenic therapy targeting these molecules represents a promising new strategy for pancreatic cancer treatment.
• The interplay between apoptosis and angiogenesis is a critical factor in pancreatic cancer progression and therapeutic response.